Status:

COMPLETED

Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Healthy

Mycobacterium Infections, Atypical

Eligibility:

All Genders

Phase:

PHASE2

Brief Summary

This is an open label study to determine the effects of the administration of Interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculo...

Detailed Description

This is an open label study to determine the effects of the administration of Interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculo...

Eligibility Criteria

Inclusion

  • Demonstrated non-tuberculous mycobacterial infection, either disseminated or pulmonary.
  • Received medical treatment for at least 3 months without improvement.
  • Preserved renal, hepatic and hematologic function.
  • Negative pregnancy urine and effective contraceptive.
  • Age range greater than 5.
  • No secondary immunodeficiency such as HIV or malignancy.
  • Not currently receiving cytotoxic therapy within the past 3 months.
  • Not pregnant or lactating.
  • No seizure disorders.
  • No known symptomatic cardiac disease.

Exclusion

    Key Trial Info

    Start Date :

    August 1 1992

    Trial Type :

    INTERVENTIONAL

    End Date :

    November 1 2000

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT00001318

    Start Date

    August 1 1992

    End Date

    November 1 2000

    Last Update

    March 4 2008

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institute of Allergy and Infectious Diseases (NIAID)

    Bethesda, Maryland, United States, 20892